AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Association Between Tumour Amphiregulin, Epiregulin and Epidermal Growth Factor Receptor (EGFR) Expression and Response to Anti-EGFR Agents in Colorectal Cancer
Sponsor: Newcastle University
This observational or N/A phase trial investigates Colorectal Cancer Stage IV and is currently completed. Newcastle University leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jun 2024 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Mar 2024 — Jun 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
▶ Show 7 earlier versions
-
Mar 2022 — Mar 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Dec 2021 — Mar 2022 [monthly]
Recruiting
-
Oct 2021 — Dec 2021 [monthly]
Recruiting
Status: Suspended → Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Suspended
-
Nov 2020 — Jan 2021 [monthly]
Suspended
-
Apr 2020 — Nov 2020 [monthly]
Suspended
Status: Not Yet Recruiting → Suspended
-
Jul 2019 — Apr 2020 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Newcastle University
- University of Leeds
- University of Liverpool
- University of Manchester
- University of Nottingham
- University of Sheffield
For direct contact, visit the study record on ClinicalTrials.gov .